Gilead exercises option for Kymera's cancer drug candidate KT-200
Go back to Gilead exercises option for Kymera's cancer drug candidate KT-200| Gilead Sciences (NASDAQ: GILD) | Delayed: 144.07 -0.74 (0.51%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $144.81 | 52 Week High | $108.63 | |||
| Open | $145.24 | 52 Week Low | $71.39 | |||
| Day High | $145.99 | P/E | 79.60 | |||
| Day Low | $143.50 | EPS | $1.81 | |||
| Volume | 1,562,225 | |||||
| (NASDAQ: KYMR) | Delayed: 114.46 -2.54 (2.17%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $117.00 | 52 Week High | $ | |||
| Open | $118.40 | 52 Week Low | $ | |||
| Day High | $119.93 | P/E | N/A | |||
| Day Low | $113.74 | EPS | $ | |||
| Volume | 163,092 | |||||
